Suppr超能文献

一名蛛网膜下腔出血患者首次诊断为因子 XI 缺乏症。

First diagnosis of factor XI deficiency in a patient with subarachnoid haemorrhage.

作者信息

Vasileiadis Ioannis, El-Ali Mahmoud, Nanas Serafim, Kolias Spyros, Zacharatos Panayotis, Christopoulou-Cokkinou Vassiliki, Kotanidou Anastasia

机构信息

First Department of Pulmonary and Critical Care Medicine, Medical School, Evaggelismos Hospital, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Blood Coagul Fibrinolysis. 2009 Jun;20(4):309-13. doi: 10.1097/MBC.0b013e328329e485.

Abstract

Aneurismal subarachnoid haemorrhage (SAH) is a devastating event affecting patients at a fairly young age and accounting for significant morbidity and mortality. Although there is progress concerning diagnostic methods and treatment, this case report might add interesting data to the current understanding of this disease and its clinical management with respect to circumstantial deficiency of the coagulation factor XI (FXI). In this report, we present a unique case of aneurismal SAH in a patient with underlying coagulation FXI deficiency which was incidentally identified after patient's admission, as routine blood tests revealed increased activated partial thromboplastin time. Despite early successful treatment with coiling, the patient had a second episode of SAH a few months after his discharge, due to aneurysm revascularization and rupture. Molecular analysis and identification of new mutations were performed. We describe management of SAH with respect to a coexisting bleeding disorder; also testing of patient's family members for FXI deficiency and decisions about screening for intracranial aneurysm are described. Late complications of SAH are - among others - aneurysm revascularization and rebleeding. Although FXI deficiency could be considered an exacerbating factor, it cannot be definitely implicated.

摘要

动脉瘤性蛛网膜下腔出血(SAH)是一种严重的疾病,多影响较为年轻的患者,且会导致较高的发病率和死亡率。尽管在诊断方法和治疗方面已有进展,但本病例报告可能会为当前对该疾病及其临床管理的理解增添有趣的数据,尤其是关于凝血因子XI(FXI)间接缺乏的情况。在本报告中,我们呈现了一例独特的动脉瘤性SAH病例,患者存在潜在的FXI缺乏,在患者入院后通过常规血液检查发现活化部分凝血活酶时间延长而偶然确诊。尽管早期通过栓塞治疗成功,但患者出院数月后因动脉瘤再通和破裂发生了第二次SAH。我们进行了分子分析并鉴定了新的突变。我们描述了针对并存出血性疾病的SAH管理;还介绍了对患者家庭成员进行FXI缺乏检测以及关于颅内动脉瘤筛查的决策。SAH的晚期并发症包括动脉瘤再通和再出血等。尽管FXI缺乏可被视为一个加重因素,但不能确定其必然关联。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验